Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey S Berger

Showing results (1-10 of 405) with videos related to

Pageof 41
Sort By:
JAMA|March 4, 2010
Aspirin as preventive therapy in patients with asymptomatic vascular diseaseJeffrey S Berger
The New England Journal of Medicine|May 25, 2022
Bleeding Outcomes after Noncardiac Surgery - Are We POISEd to Do Better?Jeffrey S Berger
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|July 11, 2018
Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary SyndromeJeffrey S Berger
The American Journal of Cardiology|August 22, 2009
Platelet-directed therapies and coronary artery bypass graftingJeffrey S Berger
Lancet (London, England)|November 15, 2017
Antithrombotic therapy in peripheral artery diseaseJeffrey S Berger
The American Journal of Cardiology|June 12, 2013
Aspirin, clopidogrel, and ticagrelor in acute coronary syndromesJeffrey S Berger
JAMA Network Open|April 26, 2022
Aspirin for Primary Prevention-Time to Rethink Our ApproachJeffrey S Berger
Journal of Thrombosis and Thrombolysis|May 13, 2011
Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the dataGaurav Sharma, Jeffrey S Berger
Vascular Medicine (London, England)|March 21, 2020
Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and managementMarie Hogan, Jeffrey S Berger
Evidence-Based Medicine|February 9, 2011
Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with standard dose but increases risk of major bleedingAnuradha Lala, Jeffrey S Berger
Pageof 41

Showing results (1-10 of 405) with videos related to

Sort By:
Pageof 41
JAMA|March 4, 2010
Aspirin as preventive therapy in patients with asymptomatic vascular diseaseJeffrey S Berger
The New England Journal of Medicine|May 25, 2022
Bleeding Outcomes after Noncardiac Surgery - Are We POISEd to Do Better?Jeffrey S Berger
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|July 11, 2018
Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary SyndromeJeffrey S Berger
The American Journal of Cardiology|August 22, 2009
Platelet-directed therapies and coronary artery bypass graftingJeffrey S Berger
Lancet (London, England)|November 15, 2017
Antithrombotic therapy in peripheral artery diseaseJeffrey S Berger
The American Journal of Cardiology|June 12, 2013
Aspirin, clopidogrel, and ticagrelor in acute coronary syndromesJeffrey S Berger
JAMA Network Open|April 26, 2022
Aspirin for Primary Prevention-Time to Rethink Our ApproachJeffrey S Berger
Journal of Thrombosis and Thrombolysis|May 13, 2011
Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the dataGaurav Sharma, Jeffrey S Berger
Vascular Medicine (London, England)|March 21, 2020
Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and managementMarie Hogan, Jeffrey S Berger
Evidence-Based Medicine|February 9, 2011
Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with standard dose but increases risk of major bleedingAnuradha Lala, Jeffrey S Berger
Pageof 41